CytomX Therapeutics, Inc. (NASDAQ:CTMX) Director Frederick W. Gluck sold 10,000 shares of the company’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $24.27, for a total value of $242,700.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

CytomX Therapeutics, Inc. (CTMX) traded down 2.54% on Friday, hitting $21.50. The stock had a trading volume of 215,136 shares. The firm has a 50-day moving average of $17.15 and a 200 day moving average of $15.67. CytomX Therapeutics, Inc. has a 52 week low of $9.85 and a 52 week high of $24.67. The company’s market capitalization is $792.64 million.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.30). CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. The business had revenue of $8.75 million during the quarter, compared to analysts’ expectations of $4.95 million. On average, analysts predict that CytomX Therapeutics, Inc. will post ($1.47) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/06/cytomx-therapeutics-inc-ctmx-director-sells-242700-00-in-stock.html.

Several hedge funds have recently bought and sold shares of the company. FMR LLC raised its stake in shares of CytomX Therapeutics by 0.6% in the second quarter. FMR LLC now owns 5,512,459 shares of the biotechnology company’s stock worth $85,444,000 after purchasing an additional 34,732 shares during the last quarter. Perceptive Advisors LLC raised its stake in shares of CytomX Therapeutics by 65.7% in the first quarter. Perceptive Advisors LLC now owns 1,530,659 shares of the biotechnology company’s stock worth $26,434,000 after purchasing an additional 606,896 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of CytomX Therapeutics by 12.2% in the second quarter. Vanguard Group Inc. now owns 924,138 shares of the biotechnology company’s stock worth $14,323,000 after purchasing an additional 100,607 shares during the last quarter. EcoR1 Capital LLC purchased a new position in shares of CytomX Therapeutics in the first quarter worth $13,729,000. Finally, Redmile Group LLC raised its stake in shares of CytomX Therapeutics by 2.4% in the second quarter. Redmile Group LLC now owns 698,392 shares of the biotechnology company’s stock worth $10,825,000 after purchasing an additional 16,500 shares during the last quarter. Hedge funds and other institutional investors own 59.97% of the company’s stock.

A number of research analysts have issued reports on the company. BidaskClub downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Cann restated a “hold” rating on shares of CytomX Therapeutics in a research note on Tuesday, August 8th. Cowen and Company restated an “outperform” rating on shares of CytomX Therapeutics in a research note on Thursday. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of CytomX Therapeutics in a research note on Wednesday. Finally, Bank of America Corporation upped their price objective on CytomX Therapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday. Two analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $32.67.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.